Palisade Bio Inc.

PALI | NASDAQ

Price Alert Chart Builder DCF Calculator

$1.61

-$0.08 (-4.73%)

Sep 22, 2026, 12:48 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-4.73%

(1D)

Rating

Updated: Aug 11, 2026

Fundamentals Weak

Market Sentiment Bullish

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $280.33M

1D Range

1.61 1.71

52W Range

0.62 2.86

Valuation (TTM)

PE -3.19

PB 2.41

EV/EBITDA -5.06

Valuation (NTM)

Forward PE N/A

Forward PEG -0.13

Price Target $4.50

Cash Flow

FCF Yield -6.2%

SBC Adj. FCF Yield -10.6%

SBC Impact -70.9%

Margins

Gross Margin 100.0%

Operating Margin -7069.8%

FCF Margin -3638.0%

Growth (CAGR)

Revenue 3Y | 5Y 26.0% | 50.0%

Dil EPS 3Y | 5Y 113.7% | 21.0%

FCF 3Y | 5Y -22.9% | -6.7%

Returns

ROA -25.1%

ROE -33.5%

ROIC -29.0%

Financial Health

Net Cash

$125.17M

Current Ratio 24.26

Interest Coverage -5,891.50

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the ...

Sector Healthcare

Industry Biotechnology

Employees 14

IPO Date Mar 29, 2007

Website www.palisadebio.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 9, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞